paediatrics Brussels 17

1456 / 1708

Articles
Vol 8 August 2007 705
5 Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy
and deferred radiotherapy in infants with malignant brain tumors: a
report from the Children’s Cancer Group. J Clin Oncol 2005;
23: 7621–31.
6 Geyer JR, Zeltzer PM, Boyett JM, et al. Survival of infants with
primitive neuroectodermal tumors or malignant ependymomas of
the CNS treated with eight drugs in 1 day: a report from the
Childrens Cancer Group. J Clin Oncol 1994; 12: 1607–15.
7 Rogers L, Pueschel J, Spetzler R, et al. Is gross-total resection
sufficient treatment for posterior fossa ependymomas? J Neurosurg
2005; 102: 629–36.
8 Copeland DR, deMoor C, Moore BD 3rd, Ater JL. Neurocognitive
development of children after a cerebellar tumor in infancy: a
longitudinal study. J Clin Oncol 1999; 17: 3476–86.
9 Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE. Late
neurocognitive sequelae in survivors of brain tumours in childhood.
Lancet Oncol 2004; 5: 399–408.
10 Riva D, Giorgi C. The neurodevelopmental price of survival in
children with malignant brain tumours. Childs Nerv Syst 2000;
16: 751–54.
11 Spiegler BJ, Bouffet E, Greenberg ML, Rutka JT, Mabbott DJ.
Change in neurocognitive functioning after treatment with cranial
radiation in childhood. J Clin Oncol 2004; 22: 706–13.
12 Duffner PK, Krischer JP, Horowitz ME, et al. Second malignancies
in young children with primary brain tumors following treatment
with prolonged postoperative chemotherapy and delayed irradiation:
a Pediatric Oncology Group study. Ann Neurol 1998; 44: 313–16.
13 Lannering B, Marky I, Lundberg A, Olsson E. Long-term sequelae
after pediatric brain tumors: their effect on disability and quality of
life.Med Pediatr Oncol 1990; 18: 304–10.
14 Spoudeas H, Kirkham F. Toxicity and late effects. In: Walker DA,
Perilongo G, Punt JAG, Taylor RE, eds. Brain and spine tumours of
childhood. London: Arnold, 2004: 433–62.
15 White L, Kellie S, Gray E, et al. Postoperative chemotherapy in
children less than 4 years of age with malignant brain tumors:
promising initial response to a VETOPEC-based regimen. A study
of the Australian and New Zealand Children’s Cancer Study Group
(ANZCCSG).J Pediatr Hematol Oncol 1998; 20: 125–30.
16 Lashford L, Campbell RH, Gattamaneni HR, et al. An intensive
multiagent chemotherapy regimen for brain tumours occurring in
very young children. Arch Dis Child 1996; 74: 219–23.
17 Gnekow AK. Recommendations of the Brain Tumor Subcommittee
for the reporting of trials. SIOP Brain Tumor Subcommittee.
International Society of Pediatric Oncology. Med Pediatr Oncol 1995;
24: 104–08.
18 Wiestler O, Schiffer D, Coons S, Prayson R. Rosenblum MR.
Ependymoma. In: Kleihues P, ed. Pathology and genetics of
tumours of the nervous system. Lyon: IARC 2000: 71–81.
19 Tai B-C, White I, Gebski V, Machin D. Competing risks analysis of
patients with osteosarcoma: a comparison of four different
approaches. Stat Med 2001; 20: 661–84.
20 Machin D, Chung Y-B, Parmar M. Survival analysis: a practical
approach, 2nd edn. Chichester: Wiley, 2006.
21 Lewis I, Weeden S, Machin D, Stark D, Craft A. Received dose and
dose-intensity of chemotherapy in non metastatic extremity
osteosarcoma. J Clin Oncol 2000; 18: 4028–37.
22 Duffner PK, Krischer JP, Sanford RA, et al. Prognostic factors in
infants and very young children with intracranial ependymomas.
Pediatr Neurosurg 1998; 28: 215–22.
23 Goldwein JW, Glauser TA, Packer RJ, et al. Recurrent intracranial
ependymomas in children. Survival, patterns of failure, and
prognostic factors. Cancer 1990; 66: 557–63.
24 Rousseau P, Habrand JL, Sarrazin D, et al. Treatment of intracranial
ependymomas of children: review of a 15-year experience.
Int J Radiat Oncol Biol Phys 1994; 28: 381–86.
25 Grundy R, Machin D, Weston C, et al. The role of chemotherapy in
intracranial ependymoma in young children: a European meta-
analysis.Neuro-Oncol 2007; 9: 217.
26 Perilongo G, Massimino M, Sotti G, et al. Analyses of prognostic
factors in a retrospective review of 92 children with ependymoma:
Italian Pediatric Neuro-oncology Group. Med Pediatr Oncol 1997;
29: 79–85.
27 Pollack IF, Gerszten PC, Martinez AJ, et al. Intracranial
ependymomas of childhood: long-term outcome and prognostic
factors. Neurosurgery 1995; 37: 655–66.
28 Robertson PL, Zeltzer PM, Boyett JM, et al. Survival and prognostic
factors following radiation therapy and chemotherapy for
ependymomas in children: a report of the Children’s Cancer Group.
J Neurosurg 1998; 88: 695–703.
29 Goldwein JW, Leahy JM, Packer RJ, et al. Intracranial ependymomas
in children. Int J Radiat Oncol Biol Phys 1990; 19: 1497–502.
30 Sutton LN, Goldwein J, Perilongo G, et al. Prognostic factors in
childhood ependymomas. Pediatr Neurosurg 1990; 16: 57–65.
31 Korshunov A, Golanov A, Sycheva R, Timirgaz V. The histologic
grade is a main prognostic factor for patients with intracranial
ependymomas treated in the microneurosurgical era: an analysis of
258 patients. Cancer 2004; 100: 1230–37.
32 Figarella-Branger D, Civatte M, Bouvier-Labit C, et al. Prognostic
factors in intracranial ependymomas in children. J Neurosurg 2000;
93: 605–13.
33 Horn B, Heideman R, Geyer R, et al. A multi-institutional
retrospective study of intracranial ependymoma in children:
identification of risk factors. J Pediatr Hematol Oncol 1999;
21: 203–11.
34 Timmermann B, Kortmann RD, Kuhl J, et al. Combined
postoperative irradiation and chemotherapy for anaplastic
ependymomas in childhood: results of the German prospective
trials HIT 88/89 and HIT 91. Int J Radiat Oncol Biol Phys 2000;
46: 287–95.
35 Poltinnikov IM, Merchant TE. CSF cytology has limited value in the
evaluation of patients with ependymoma who have MRI evidence of
metastasis. Paediatr Blood Cancer 2006; 47: 169–73.
36 Peet A, Leach M, Pinkerton C, Price P, Williams S, Grundy R. The
development of functional imaging in the diagnosis, management
and understanding of childhood brain tumours.
Pediatr Blood Cancer 2006; 44: 103–13.
37 Weitman SD, Frazier KM, Kamen BA. The folate receptor in central
nervous system malignancies of childhood. J Neurooncol 1994;
21: 107–12.
38 Gumley D, Phipps K, Reynolds J, Michalski A. Infants with
ependymoma: Outcome following surgery and baby brain
chemotherapy. Neuro-Oncol 2004; 6: 457.
39 Abelson HT. Methotrexate and central nervous system toxicity.
Cancer Treat Rep 1978; 62: 1999–2001.
40 Bleyer WA. Neurologic sequelae of methotrexate and ionizing
radiation: a new classification. Cancer Treat Rep 1981;
65 (suppl 1): 89–98.
41 Allen JC, Rosen G, Mehta BM, Horten B. Leukoencephalopathy
following high-dose iv methotrexate chemotherapy with leucovorin
rescue. Cancer Treat Rep 1980; 64: 1261–73.
42 Kellie SJ, Chaku J, Lockwood LR, O’Regan P, Waters KD, Wong CK.
Late magnetic resonance imaging features of leukoencephalopathy
in children with central nervous system tumours following high-
dose methotrexate and neuraxis radiation therapy. Eur J Cancer
2005; 41: 1588–96.
43 Rutkowski S, Bode U, Deinlein F, et al. Treatment of early
childhood medulloblastoma by postoperative chemotherapy alone.
N Engl J Med 2005; 352: 978–86.
44 Allen JC, Walker R, Rosen G. Preradiation high-dose intravenous
methotrexate with leucovorin rescue for untreated primary
childhood brain tumors. J Clin Oncol 1988; 6: 649–53.
45 van Veelen-Vincent ML, Pierre-Kahn A, Kalifa C, et al.
Ependymoma in childhood: prognostic factors, extent of surgery,
and adjuvant therapy. J Neurosurg 2002; 97: 827–35.
46 Salazar OM, Castro-Vita H, VanHoutte P, Rubin P, Aygun C.
Improved survival in cases of intracranial ependymoma after
radiation therapy. Late report and recommendations. J Neurosurg
1983; 59: 652–59.
47 Shaw EG, Evans RG, Scheithauer BW, Ilstrup DM, Earle JD.
Postoperative radiotherapy of intracranial ependymoma in pediatric
and adult patients. Int J Radiat Oncol Biol Phys 1987; 13: 1457–62.